Novel compounds for the treatment of HIV type-1 infection (Q37502492)

20 August 2017

1 reference

title

Novel compounds for the treatment of HIV type-1 infection (English)

1 reference

20 August 2017

author

Hans-Jürgen Stellbrink

series ordinal

1

object named as

Hans-Jürgen Stellbrink

0 references

author name string

Hans-Jürgen Stellbrink

series ordinal

1

1 reference

20 August 2017

publication date

1 January 2009

1 reference

Antiviral Chemistry & Chemotherapy

20 August 2017

published in

1 reference

20 August 2017

volume

19

1 reference

20 August 2017

issue

5

1 reference

20 August 2017

page(s)

189-200

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

High frequency of highly active antiretroviral therapy modifications in patients with acute or early human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Stability of antiretroviral regimens in patients with viral suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

The use of beta-D-2,6-diaminopurine dioxolane with or without mycophenolate mofetil in drug-resistant HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Raltegravir with optimized background therapy for resistant HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Safety and pharmacokinetics of Bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Maraviroc for previously treated patients with R5 HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Novel 4'-substituted stavudine analog with improved anti-human immunodeficiency virus activity and decreased cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Intracellular metabolism and pharmacokinetics of 5'-hydrogenphosphonate of 3'-azido-2',3'-dideoxythymidine, a prodrug of 3'-azido-2',3'-dideoxythymidine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Phosphoramidate and phosphate prodrugs of (-)-beta-D-(2R,4R)-dioxolane-thymine: synthesis, anti-HIV activity and stability studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Pharmacology and pharmacokinetics of the antiviral agent beta-D-2',3'-dideoxy-3'-oxa-5-fluorocytidine in cells and rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

4'-Ethynylstavudine (4'-Ed4T) has potent anti-HIV-1 activity with reduced toxicity and shows a unique activity profile against drug-resistant mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Anti-human immunodeficiency virus type 1 activity and resistance profile of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

2'-deoxy-4'-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Safety and pharmacokinetic profile of multiple escalating doses of (+)-calanolide A, a naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy HIV-negative volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Safety and pharmacokinetics of single doses of (+)-calanolide a, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Pharmacokinetics of BILR 355 after multiple oral doses coadministered with a low dose of ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Binding modes of two novel non-nucleoside reverse transcriptase inhibitors, YM-215389 and YM-228855, to HIV type-1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Diphenyl ether non-nucleoside reverse transcriptase inhibitors with excellent potency against resistant mutant viruses and promising pharmacokinetic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Antiviral activity and cross-resistance profile of P-1946, a novel human immunodeficiency virus type 1 protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Safety and pharmacokinetics of GSK364735, a human immunodeficiency virus type 1 integrase inhibitor, following single and repeated administration in healthy adult subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Phase I/II dose escalation and randomized withdrawal study with add-on azodicarbonamide in patients failing on current antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

6th international symposium on retroviral nucleocapsid

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody (TNX-355) and enfuvirtide (T-20).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

The appealing story of HIV entry inhibitors : from discovery of biological mechanisms to drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Anti-HIV activity and resistance profile of the CXC chemokine receptor 4 antagonist POL3026.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

A fusion inhibitor (FP-21399) for the treatment of human immunodeficiency virus infection: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Pharmacokinetics of sifuvirtide, a novel anti-HIV-1 peptide, in monkeys and its inhibitory concentration in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

New class of HIV drugs shows promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Liposomal encapsulation enhances antiviral efficacy of SPC3 against human immunodeficiency virus type-1 infection in human lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Neurokinin-1 receptor antagonist (aprepitant) inhibits drug-resistant HIV-1 infection of macrophages in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Update on anti-CTLA-4 antibodies in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Identification of cellular deoxyhypusine synthase as a novel target for antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Oxadiazols: a new class of rationally designed anti-human immunodeficiency virus compounds targeting the nuclear localization signal of the viral matrix protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

A passive immunotherapy, (PE)HRG214, in patients infected with human immunodeficiency virus: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

A phase I study of the pharmacokinetics and safety of passive immunotherapy with caprine anti-HIV antibodies, (PE)HRG214, in HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020901900502

10.1177/095632020901900502

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference